Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 807 participants.
Also called NCT01499082
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 807 participants
- Sponsor
- Registry
-
NCT01499082 -
2010-023769-23
-
- Main results
- New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Estonia, Finland, France, Germany, Hungary, Latvia, Mexico, Netherlands, Romania, South Africa
- Registry status
- Completed
Technical summary
Registry record NCT01499082. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2015-04-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
- Acronym
- EDITION I
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- HOE901-U300 (new formulation of insulin glargine)
- Intervention (Drug)
- Lantus (insulin glargine)
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01499082- Content hash
00380a30921ceb8b6ea94e59a094fcbd683eb36db5481f95a04a00183d230986